Does a Patient Support Program Cover Medication Cost in Egypt? A Patient's Guide

Short answer: sometimes, but not by default. A patient support program (PSP) is a service run or sponsored by a drug company that may include education, nurse follow-up, reminders, testing support or a medicine pricing scheme, but each programme sets its own terms. A PSP is not health insurance. Ask what is covered in writing before you join. This guide is educational and does not replace medical advice.

• No universal rule exists. The Newfoundland and Labrador Prescription Drug Plan, which lists manufacturer programmes for biologic medicines, notes that services "may not be available for all biologic products", that many programmes describe services for "eligible patients" without listing criteria, and that financial assistance is typically assessed case by case.
• Typical PSP services listed by that plan include a single point of contact such as a nurse case manager, help with reimbursement and authorisation paperwork, financial assistance, injection training, adherence calls, delivery and pharmacy coordination. Not every programme offers all of them.
• Egypt example: Roche's Perjeta (pertuzumab) patient support programme, running since 1 January 2016 for women with HER2-positive breast cancer, offered a pricing scheme of "a free vial on each 2 vials purchased". Its only stated requirement was that the patient purchases the drug herself, because the report says the drug is not reimbursed in the public system.
• The same programme sponsored HER2 testing for all breast cancer patients in Egypt, whether or not they enrolled, and sponsored echo, CT and brain MRI or PET scans every three cycles, per the report.
• Before you share personal or health information, ask the programme how it is collected, used and protected: the Newfoundland page itself says it gives no information on this and advises asking each programme.

What a patient support program is, and what it may include

A PSP is a package of services around a medicine, usually funded or sponsored by the manufacturer and often delivered by a nurse team, pharmacy or call centre working for the sponsor. The Newfoundland and Labrador drug plan describes typical elements: a single point of contact, help navigating reimbursement and special authorisation paperwork, financial assistance and in some programmes a temporary bridging supply, injection training in clinic, at home or virtually, adherence calls and monitoring, lab testing and vaccination support, medication delivery and pharmacy coordination, and in a few programmes infusion clinic access, lifestyle apps or travel assistance. Some products have no formal programme at all, and the plan notes that contact details and services may change, so confirm them with the programme or manufacturer. The point for Egyptian patients: the word 'support' can mean anything from a leaflet and a reminder call to a price scheme, so never assume.

Does a PSP pay for the medicine? Three kinds of support

It helps to separate three things a programme might offer. First, price or supply support: a discount, a free-vial scheme, a bridging supply or a payment plan. Second, service support: nurse education, injection training, reminders, home visits and coordination of appointments. Third, testing and access support: sponsored diagnostics or help with authorisation paperwork. A programme can offer one without the others. Only the first kind reduces what you pay for the medicine, and it is always governed by the sponsor's written terms and, in Egypt, by what your insurer or the public system reimburses. If a programme brochure says 'support', ask which of the three it means.

A documented Egyptian example: Roche's Perjeta programme

A case report on the Access Accelerated resource library describes Roche's Perjeta patient support programme in Egypt, which started on 1 January 2016 to help women with HER2-positive breast cancer access pertuzumab. The report states that the medicine is not reimbursed in the public system and is available only in the private sector. The pricing scheme offered a free vial on each two vials purchased, and the only eligibility condition it lists is that the patient buys the medicine herself. Healthcare providers gave patients an overview, a membership card and an educational brochure, and a third-party call centre handled registration and sent dose reminders. The sponsor also paid for HER2 testing for all breast cancer patients in Egypt, enrolled or not. The report gives programme figures for 2017, 2018 and 2019: patients reached with the pricing scheme 72, 132 and 240; patients enrolled in the support programme 45, 78 and 108. It also reports patients adherent to treatment of 32%, 45% and 48%. These are sponsor-reported figures without an independent evaluation, and the definition of adherence is not given in the report, so treat them as the programme's own numbers. The lesson: in this example, the programme reduced the cost of part of the treatment course through a pricing scheme, but it did not make the medicine free and it required the patient to buy it.

PSP, health insurance and public coverage are different things

A PSP is a manufacturer-sponsored service, not an insurance policy. Whether your insurer or a public programme pays for a medicine is decided by that payer, under its own rules and approvals, not by the PSP. Ask your insurer separately about authorisation for the medicine, and ask the programme whether its support applies on top of insurance, instead of insurance, or only when you pay privately. The Egyptian example above applied to patients who bought the medicine themselves. Do not cancel or delay an insurance authorisation because a programme has offered a discount.

How patients usually join

The Newfoundland page notes that enrolment usually involves a healthcare provider or the patient completing an enrolment form, or contacting the programme by phone or email, and that some programmes route enrolment through a specialist or trained pharmacist. In the Egyptian example, providers handed over a membership card and brochure and a third-party call centre registered patients. In practice: your doctor or pharmacist tells you whether a programme exists for your prescribed medicine, you complete an enrolment form, you sign a consent for the use of your data, and a coordinator contacts you. Our guide on consent and privacy in patient support programmes explains what to look for in that consent form.

What critics say, and what to watch for

A July 2026 article in Pharmaceutical Commerce on what makes patient support programmes work lists criticisms: that clinicians working for manufacturers may not give fully unbiased advice, that enrolment is complex and fragmented across manufacturers, that copay assistance may reduce price sensitivity and let manufacturers sustain high list prices, and that manufacturers rarely disclose utilisation, costs or outcomes. The article is by consultants and says effectiveness claims rest largely on one 2010 multiple sclerosis study, so these are arguments, not settled findings. For patients, the practical lesson is simple: your doctor, not the programme, decides your treatment, and you can ask whether the programme's advice is independent of the sponsor's commercial interest.

An illustrative scenario in Alexandria

This example is illustrative, not a real case. A patient in Alexandria is prescribed a specialist injectable medicine and is handed a leaflet about a manufacturer's support programme. She asks the doctor's clinic three things: is there a programme for this medicine in Egypt, who runs it, and what exactly does it cover? The coordinator explains in writing that the programme provides nurse education and reminder calls but no price reduction, and that a separate pricing scheme applies only to patients who pay privately. She asks her insurer for authorisation first, keeps the programme's terms with her prescription, and reads the consent form before signing. The point: ask in writing, separate the three kinds of support, and check insurance independently.

Eight questions to ask before you join a PSP

• Who sponsors and who runs this programme, and who will contact me?
• Which services are offered: price or supply support, nurse education and reminders, testing, home visits?
• Does the programme reduce what I pay for the medicine, by how much, and under what written conditions?
• Does it work with my insurance, instead of it, or only if I pay privately?
• What must I do to stay enrolled, and can I leave at any time?
• What personal and health data are collected, who sees them, and for what purpose?
• What happens if I report a side effect or stop the medicine?
• Is there a cost to me for any service, and is it written in the terms?

How Hospitalia can help

Hospitalia is an Egypt-based integrated home healthcare and corporate medical services platform. Its patient support services cover onboarding, education, follow-up and care coordination for programmes whose sponsors define the scope; funding terms, if any, are set by the programme sponsor, not by the team delivering the support. Our overview of patient support programmes in Egypt explains how programmes work, and our guide on consent and privacy explains what to check before you sign.